Dr Tom P Shakespeare

All Stories

1. 
   Can we avoid high levels of dose escalation for high-risk prostate cancer in the setting of androgen deprivation?

   Article • OncoTargets and Therapy, May 2016, Dove Medical Press

   Dr Tom P Shakespeare, Dr Noel John Aherne

2. 
   Can we avoid dose escalation for intermediate-risk prostate cancer in the setting of short-course neoadjuvant androgen deprivation?

   Article • OncoTargets and Therapy, March 2016, Dove Medical Press

   Dr Noel John Aherne, Dr Tom P Shakespeare